Edwards Lifesciences Co. Forecasted to Earn Q2 2025 Earnings of $0.78 Per Share (NYSE:EW)

Edwards Lifesciences Co. (NYSE:EW) – Equities research analysts at Leerink Partnrs dropped their Q2 2025 EPS estimates for shares of Edwards Lifesciences in a report issued on Wednesday, July 17th. Leerink Partnrs analyst M. Kratky now forecasts that the medical research company will post earnings of $0.78 per share for the quarter, down from their prior forecast of $0.79. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.77 per share.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The firm had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion.

A number of other analysts have also commented on the stock. Royal Bank of Canada lifted their price target on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a research note on Monday, April 15th. Piper Sandler lifted their price target on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a research note on Friday, April 26th. StockNews.com upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Thursday, June 27th. The Goldman Sachs Group started coverage on shares of Edwards Lifesciences in a research report on Thursday, May 30th. They set a “buy” rating and a $107.00 target price for the company. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their target price for the company from $86.00 to $103.00 in a research report on Tuesday, May 14th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average target price of $96.13.

Edwards Lifesciences Trading Up 0.8 %

Shares of NYSE EW opened at $86.50 on Friday. Edwards Lifesciences has a 1 year low of $60.57 and a 1 year high of $96.12. The stock has a market cap of $52.12 billion, a P/E ratio of 37.28, a price-to-earnings-growth ratio of 3.14 and a beta of 1.11. The firm has a 50-day moving average of $89.11 and a 200 day moving average of $86.82. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67.

Hedge Funds Weigh In On Edwards Lifesciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Dynamic Advisor Solutions LLC lifted its stake in Edwards Lifesciences by 4.4% during the fourth quarter. Dynamic Advisor Solutions LLC now owns 16,142 shares of the medical research company’s stock worth $1,176,000 after purchasing an additional 687 shares during the last quarter. Brookstone Capital Management lifted its stake in Edwards Lifesciences by 8.1% during the fourth quarter. Brookstone Capital Management now owns 11,892 shares of the medical research company’s stock worth $907,000 after purchasing an additional 892 shares during the last quarter. IFM Investors Pty Ltd lifted its stake in Edwards Lifesciences by 2.1% during the fourth quarter. IFM Investors Pty Ltd now owns 135,565 shares of the medical research company’s stock worth $10,337,000 after purchasing an additional 2,792 shares during the last quarter. RDA Financial Network lifted its stake in Edwards Lifesciences by 13.1% in the fourth quarter. RDA Financial Network now owns 23,487 shares of the medical research company’s stock valued at $1,791,000 after buying an additional 2,729 shares during the last quarter. Finally, Advisor Resource Council purchased a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $552,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In other news, CEO Bernard J. Zovighian bought 580 shares of the company’s stock in a transaction on Monday, May 6th. The stock was bought at an average cost of $85.74 per share, with a total value of $49,729.20. Following the transaction, the chief executive officer now directly owns 3,268 shares in the company, valued at approximately $280,198.32. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, CFO Scott B. Ullem sold 7,250 shares of the business’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $85.80, for a total transaction of $622,050.00. Following the completion of the transaction, the chief financial officer now directly owns 19,074 shares of the company’s stock, valued at $1,636,549.20. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Bernard J. Zovighian acquired 580 shares of the stock in a transaction dated Monday, May 6th. The shares were bought at an average cost of $85.74 per share, with a total value of $49,729.20. Following the completion of the transaction, the chief executive officer now owns 3,268 shares of the company’s stock, valued at approximately $280,198.32. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 81,099 shares of company stock worth $7,003,553. Company insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.